Webinar: Impact of CYP2D6 Pharmacogenomics on Oncology Care

DNA strand for Precision Medicine

Webinar: Impact of CYP2D6 Pharmacogenomics on Oncology Care



Webinar Summary:

CYP2D6 is an important pharmacogenetics (PGx) gene as it is involved in the metabolism of ~25% of clinically prescribed drugs. Dr. Cyrine-Eliana Haidar at St Jude Children’s Research Hospital will discuss how to use CYP2D6 genetic information to guide drug dosing and improve patient care, with focus on her many years of experience in managing the medications that are important in oncology care, including ondansetron, tamoxifen, select antidepressants and pain medicines.

About Speaker

Dr. Haidar is the Clinical Pharmacogenetics Coordinator at St. Jude Children’s Research Hospital. She leads the clinical implementation of PGx and is the principal investigator of the institution wide PG4KDS protocol. She is the program coordinator for St. Jude’s ASHP-accredited PGY2 Clinical Pharmacogenomics Residency and an Assistant Professor of Clinical Pharmacy at The University of Tennessee Health Science Center. She is an active member of the Clinical Pharmacogenetics Consortium (CPIC) and has authored 5 CPIC guidelines to date. Dr. Haidar is a founding member of the New Pharmacogenomics Research Network (PGRN).


CYP2D6 testing

Learn more about RPRD’s CYP2D6 testing

Gene details

Learn more about CYP2D6 gene and the relevant CPIC guidelines